300831-07-6

Basic information

• Product Name: 2-Thiazolecarboxamide, N-(2-acetyl-5-methoxyphenyl)-4-(1-methylethyl)-
• CAS NO: 300831-07-6
• Molecular Formula: C16H18N2O3S
• Molecular Weight: 318.397
• Mol File: 300831-07-6.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-Thiazolecarboxamide, N-(2-acetyl-5-methoxyphenyl)-4-(1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolecarboxamide, N-(2-acetyl-5-methoxyphenyl)-4-(1-methylethyl)-(300831-07-6)
• EPA Substance Registry System: 2-Thiazolecarboxamide, N-(2-acetyl-5-methoxyphenyl)-4-(1-methylethyl)-(300831-07-6)

Safety Data

• Hazardous Substances Data: 300831-07-6(Hazardous Substances Data)

Upstream product

• 1108658-73-6 4-isopropylthiazole-2-carboxylic acid 
• 19967-55-6 1-bromo-3-methyl-2-butanone 
• 156589-82-1 4-(1-methylethyl)thiazole-2-carboxylic acid ethyl ester 
• 563-80-4 3-methyl-butan-2-one 
• 536-90-3 m-Anisidine 
• 923289-59-2 4-isopropylthiazole-2-carbonyl chloride 
• 42465-53-2 1-(2-amino-4-methoxyphenyl)ethanone 
• 300831-06-5 4-isopropylthiazole-2-carboxylic acid 

Downstream Products

• 1108658-94-1 N-(6-acetyl-3-chloro-4-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 

Relevant articles and documents

Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.